Novo Nordisk A/S (NYSE:NVO) Trading Down 14.6% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO)’s share price fell 14.6% during mid-day trading on Tuesday . The stock traded as low as $49.96 and last traded at $50.3450. 69,180,715 shares were traded during trading, an increase of 185% from the average session volume of 24,258,721 shares. The stock had previously closed at $58.93.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema late?stage results show superior HbA1c and weight loss versus semaglutide, strengthening Novo’s pipeline and long?term growth prospects if approved. Novo Nordisk says CagriSema outperforms semaglutide
• Positive Sentiment: Quarterly results topped estimates (reported $1.01 EPS vs. $0.90 consensus) and full?year 2025 sales beat forecasts, confirming solid recent execution. These positives support valuation if management can offset 2026 headwinds. Novo Nordisk Posts Better-Than-Expected 2025 Sales
• Neutral Sentiment: Management named Jamey Millar head of U.S. business and Hong Chow head of product & portfolio strategy — operational moves that aim to sharpen execution in the key U.S. market. Wegovy maker Novo Nordisk appoints Jamey Millar
• Neutral Sentiment: Mixed analyst commentary: some firms (e.g., Kepler) maintained positive ratings while others caution that more head?to?head and competitive data will drive the next leg of performance. Watch upcoming readouts and guidance cadence. Citi flags bigger tests ahead after Novo Nordisk diabetes trial success
• Negative Sentiment: Company guidance: Novo forecasted a 5%–13% decline in adjusted sales and operating profit for 2026 at constant FX, explicitly citing U.S. price reductions and loss of exclusivity for key GLP?1 drugs — the primary driver of today’s selloff. Novo Nordisk warns of 2026 sales decline, shares fall
• Negative Sentiment: Market reaction: shares dropped sharply after the outlook (reports of ~11–13% declines), and trading was briefly halted as the news hit — indicating short?term volatility and forced repositioning by holders. Novo Nordisk shares tumble after company forecasts sales declines
• Negative Sentiment: Broader market context: analysts note the obesity/GLP?1 market faces pricing pressure and intensified competition, which tightens longer?term sales potential and supports a more conservative view on peak revenues. Obesity market sales potential tightens

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on NVO shares. HSBC reaffirmed a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Finally, Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $57.79.

Novo Nordisk A/S Stock Down 14.6%

The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The business has a 50-day simple moving average of $53.72 and a 200-day simple moving average of $54.28. The company has a market cap of $224.79 billion, a PE ratio of 14.64 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Institutional Trading of Novo Nordisk A/S

Several institutional investors have recently modified their holdings of the stock. LJI Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 7.9% during the fourth quarter. LJI Wealth Management LLC now owns 4,239 shares of the company’s stock worth $216,000 after purchasing an additional 309 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in Novo Nordisk A/S by 2.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 58,905 shares of the company’s stock worth $2,997,000 after buying an additional 1,540 shares during the last quarter. Patten & Patten Inc. TN boosted its holdings in Novo Nordisk A/S by 14.4% in the 4th quarter. Patten & Patten Inc. TN now owns 37,553 shares of the company’s stock worth $1,911,000 after buying an additional 4,721 shares during the last quarter. Crestwood Advisors Group LLC increased its stake in Novo Nordisk A/S by 54.5% during the 4th quarter. Crestwood Advisors Group LLC now owns 5,815 shares of the company’s stock worth $296,000 after buying an additional 2,052 shares in the last quarter. Finally, Cabot Wealth Management Inc. raised its holdings in shares of Novo Nordisk A/S by 12.3% during the fourth quarter. Cabot Wealth Management Inc. now owns 157,258 shares of the company’s stock valued at $8,001,000 after acquiring an additional 17,200 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.